BR112017004899A2 - detecção de proteínas mal dobradas - Google Patents

detecção de proteínas mal dobradas

Info

Publication number
BR112017004899A2
BR112017004899A2 BR112017004899A BR112017004899A BR112017004899A2 BR 112017004899 A2 BR112017004899 A2 BR 112017004899A2 BR 112017004899 A BR112017004899 A BR 112017004899A BR 112017004899 A BR112017004899 A BR 112017004899A BR 112017004899 A2 BR112017004899 A2 BR 112017004899A2
Authority
BR
Brazil
Prior art keywords
protein
misfolded
sample
soluble protein
incubation mixture
Prior art date
Application number
BR112017004899A
Other languages
English (en)
Inventor
K Vollrath Benedikt
Soto Jara Claudio
Shahnawaz Mohammad
M Lebovitz Russell
Original Assignee
Amprion Inc
K Vollrath Benedikt
Univ Texas
Soto Jara Claudio
Shahnawaz Mohammad
M Lebovitz Russell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amprion Inc, K Vollrath Benedikt, Univ Texas, Soto Jara Claudio, Shahnawaz Mohammad, M Lebovitz Russell filed Critical Amprion Inc
Publication of BR112017004899A2 publication Critical patent/BR112017004899A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)

Abstract

são fornecidos métodos e kits para amplificação e detecção de proteínas mal dobradas a partir de amostras, por exemplo, de pacientes com mal de alzheimer, mal de parkinson e similares. por exemplo, um método para a determinação da presença de uma proteína solúvel mal dobrada em uma amostra pode incluir o contato da amostra com uma proteína monomérica dobrada para formar uma mistura para incubação; realização de um ciclo de incubação duas ou mais vezes eficaz para formar uma porção amplificada da proteína mal dobrada; incubação da mistura para incubação eficaz para causar o dobramento incorreto e/ou agregação de pelo menos uma porção da proteína monomérica dobrada; rompimento físico da mistura para incubação eficaz para romper pelo menos uma porção de qualquer agregado de proteína presente; e determinação da presença da proteína solúvel mal dobrada na amostra através da detecção de pelo menos uma porção da proteína solúvel mal dobrada. a proteína monomérica dobrada e a proteína solúvel mal dobrada podem excluir a proteína príon (prp) e suas isoformas.
BR112017004899A 2014-09-11 2015-09-11 detecção de proteínas mal dobradas BR112017004899A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049306P 2014-09-11 2014-09-11
PCT/US2015/049844 WO2016040907A1 (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Publications (1)

Publication Number Publication Date
BR112017004899A2 true BR112017004899A2 (pt) 2017-12-12

Family

ID=55454515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004899A BR112017004899A2 (pt) 2014-09-11 2015-09-11 detecção de proteínas mal dobradas

Country Status (15)

Country Link
US (1) US20160077112A1 (pt)
EP (2) EP4292654A3 (pt)
JP (2) JP6980953B2 (pt)
KR (1) KR102448128B1 (pt)
CN (1) CN107208125A (pt)
AU (1) AU2015314783B2 (pt)
BR (1) BR112017004899A2 (pt)
CA (1) CA2960830C (pt)
ES (1) ES2953855T3 (pt)
HR (1) HRP20231232T1 (pt)
IL (2) IL251052B (pt)
MX (1) MX2017003269A (pt)
PL (1) PL3191599T3 (pt)
SG (2) SG10202008464UA (pt)
WO (1) WO2016040907A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
GB201611840D0 (en) * 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
CN110869763B (zh) * 2017-05-16 2022-07-29 安培里翁公司 错误折叠tau蛋白质的检测
WO2019070480A1 (en) * 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
JP2021508044A (ja) * 2017-12-21 2021-02-25 ハー・ルンドベック・アクチエゼルスカベット アルファ−シヌクレイン病のアッセイ、方法、及び治療
CN108088816A (zh) * 2018-01-23 2018-05-29 深圳市国赛生物技术有限公司 小型特定蛋白分析仪
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
US20190353669A1 (en) * 2018-05-16 2019-11-21 Amprion, Inc. Detection of Brain Injury or Neurological Disease using Tau Protein
US20210407625A1 (en) * 2018-09-21 2021-12-30 Deepmind Technologies Limited Machine learning for determining protein structures
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
WO2021046174A1 (en) 2019-09-04 2021-03-11 Amprion, Inc. Alpha-synuclein detection using beads
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
WO2021198098A1 (en) 2020-04-03 2021-10-07 Universität Zürich Improved method of detecting biomarkers in a biological sample
CA3199642A1 (en) * 2020-11-21 2022-05-27 Shuwen Biotech Co. Ltd. Apparatus and method for detecting misfolded protein in biological sample
WO2022221876A1 (en) * 2021-04-15 2022-10-20 The Brigham And Women's Hospital, Inc. Digital protein misfolding assays
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1299729T3 (da) 2000-07-07 2006-12-04 Applied Research Systems Tidlig diagnosticering af konformationelle sygdomme
US20030027210A1 (en) 2001-01-03 2003-02-06 Daniel Benjamin Alpha synuclein aggregation assays
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
CN101156068B (zh) * 2005-02-15 2015-03-18 阿德利夫股份有限公司 检测错折叠蛋白和朊病毒的方法
ATE528008T1 (de) * 2006-05-19 2011-10-15 Alnylam Pharmaceuticals Inc Rnai-modulation von aha und ihre therapeutische verwendung
WO2008030973A2 (en) * 2006-09-06 2008-03-13 The Board Of Regents Of The University Of Texas System Methods and compositions for the detection of protein folding disorders
JP2010043865A (ja) * 2006-12-12 2010-02-25 Olympus Corp 異常型プリオンの検出方法
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
JP6109077B2 (ja) * 2011-01-18 2017-04-05 アメリカ合衆国 プリオンの増幅および検出のための方法
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2016040903A1 (en) * 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein

Also Published As

Publication number Publication date
IL251052B (en) 2022-05-01
EP3191599A4 (en) 2018-03-14
EP4292654A2 (en) 2023-12-20
WO2016040907A1 (en) 2016-03-17
IL291809B2 (en) 2023-06-01
JP2022000629A (ja) 2022-01-04
EP4292654A3 (en) 2024-01-03
AU2015314783B2 (en) 2021-10-21
SG11201701953RA (en) 2017-04-27
US20160077112A1 (en) 2016-03-17
ES2953855T3 (es) 2023-11-16
EP3191599B1 (en) 2023-08-02
HRP20231232T1 (hr) 2024-01-19
JP6980953B2 (ja) 2021-12-15
AU2015314783A1 (en) 2017-04-27
EP3191599A1 (en) 2017-07-19
IL291809A (en) 2022-06-01
KR20170103741A (ko) 2017-09-13
SG10202008464UA (en) 2020-10-29
CA2960830C (en) 2023-09-05
JP2017530373A (ja) 2017-10-12
CA2960830A1 (en) 2016-03-17
KR102448128B1 (ko) 2022-09-27
PL3191599T3 (pl) 2023-12-27
MX2017003269A (es) 2017-12-04
EP3191599C0 (en) 2023-08-02
CN107208125A (zh) 2017-09-26
JP7104943B2 (ja) 2022-07-22
IL251052A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112017020582A2 (pt) composições e métodos para a detecção de um contaminante biológico
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
BR112018006018A2 (pt) detecção de beta-amiloide através de espectrometria de massa
BR112019005167A2 (pt) método e kit para analisar uma amostra
BR112019005172A2 (pt) método e kit para analisar uma amostra
PH12019550236A1 (en) Detection of misfolded tau protein
BR112016024624A2 (pt) produto de combinação para detectar marcador alvo
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
BR112017028627A2 (pt) dispositivo para detectar proteínas deformadas e métodos de uso mesmo
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
WO2020037250A8 (en) Stem-loop receptor-based field-effect transistor sensor devices for small-molecule target detection under physiological salt concentrations
BR112016021714A2 (pt) imunoensaio e anticorpos para a detecção de cromogranina a
SG10201907690TA (en) Device and method for detecting target molecules
BR112019005790A2 (pt) método para detectar rnas pequenos ou proteínas associadas a rnas pequenos.
BR112019005179A2 (pt) método e kit para analisar uma amostra

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2544 DE 08/10/2019 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]